About us

Triphase Accelerator acquires promising cancer therapies and accelerates their development from pre-IND to clinical proof-of-concept leveraging our deep relationships with world-class scientists, clinicians and business professionals with access to state-of-the-art facilities and capabilities.

Our expertise is concentrated on developing innovative high-value potential drug candidates that have the promise to be transformative to patients, determining whether they should be advanced through further development, and efficiently executing that advancement in a timely and cost-effective manner.

news and events

Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma...

Find out More

FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemi...

Find out More

Triphase Accelerator to Present Investigational New Drug Enabling Data for TRPH-222...

Find out More

Triphase Accelerator Reports Completion of Initial Regulatory Interactions with FDA and Health Canad...

Find out More

partner with us

Triphase Accelerator seeks to develop relationships with companies and research institutions looking to advance oncology drug candidates with substantial, but unrealized medical and commercial value. Triphase specializes in efficient and cost-effective drug development and can help realize the potential of these compounds.